secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2023-06-01T23:59:59+00:00
Accession:  0001753926-23-000765
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lipella Pharmaceuticals director David Battleman resigns effective June 17, 2023
--------------------------------------------------------------------------------

- Dr. David Battleman notified the Board on May 30, 2023 of his resignation as director.
- Resignation effective June 17, 2023, and not due to any dispute or disagreement with the Company.
- No replacement director has been announced as of the filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392623000765/0001753926-23-000765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392623000765/g083578_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-23-000765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer